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Abstract
Background: The molecular phenotype of Huntington’s disease (HD) is known to comprise highly reproducible changes in
gene expression involving striatal signaling genes. Here we test whether individual changes in striatal gene expression are
capable of mitigating HD-related neurotoxicity.
Methodology/Principal Findings: We used protein-encoding and shRNA-expressing lentiviral vectors to evaluate the effects
of RGS2, RASD2, STEP and NNAT downregulation in HD. Of these four genes, only RGS2 and RASD2 modified mutant htt
fragment toxicity in cultured rat primary striatal neurons. In both cases, disease modulation was in the opposite of the
predicted direction: whereas decreased expression of RGS2 and RASD2 was associated with the HD condition, restoring
expression enhanced degeneration of striatal cells. Conversely, silencing of RGS2 or RASD2 enhanced disease-related
changes in gene expression and resulted in significant neuroprotection. These results indicate that RGS2 and RASD2
downregulation comprises a compensatory response that allows neurons to better tolerate huntingtin toxicity. Assessment
of the possible mechanism of RGS2-mediated neuroprotection showed that RGS2 downregulation enhanced ERK activation.
These results establish a novel link between the inhibition of RGS2 and neuroprotective modulation of ERK activity.
Conclusions: Our findings both identify RGS2 downregulation as a novel compensatory response in HD neurons and
suggest that RGS2 inhibition might be considered as an innovative target for neuroprotective drug development.
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Introduction
Huntington’s disease (HD) is a hereditary neurodegenerative
disorder caused by a CAG repeat expansion mutation encoding an
abnormally long polyglutamine tract in the huntingtin (htt) protein
[1]. Accumulation of mutant htt and its polyglutamine-containing
fragments subsequently manifests as nuclear htt enrichment and the
formationof intracellularinclusion bodiesinneuronsofthestriatum
and cortex, the cells that eventually degenerate in HD [2,3,4].
Mutant htt attacks multiple cellular processes crucial for neuronal
function [5]; these include transcriptional regulation, energy
metabolism, neurotransmission, and axonal transport. One of the
earliest detectable effects of mutant htt in the brain is the
downregulation of striatal signaling genes [6,7,8]. The dysregulated
genes notably include multiple components of G-protein-coupled
receptor (GPCR)signaling cascades,a finding confirmedinmultiple
lines of mutant htt-expressing mice [9] and human HD brain [10].
A number of different mechanisms have been proposed to
explain HD-induced alterations in gene expression [11]. These
draw from evidence that mutant htt interacts with and can disrupt
the activities of a large number of transcriptional regulatory
proteins. The implicated proteins include DNA-binding transcrip-
tion factors, transcriptional co-regulators, histone-modifying en-
zymes, and the basal transcription machinery [11,12]. The relative
contributions of various transcriptional abnormalities as important
drivers of the disease process are still under active investigation.
A lesser-explored perspective on altered gene expression in HD
is the extent to which differentially expressed genes participate in
modulating htt toxicity. While it has been widely assumed that
transcriptomic changes reflect direct consequences of mutant htt
on gene regulation, this is far from being proven. In fact, some
gene expression changes may instead reflect the neuron’s
activation of autocompensatory mechanisms to counteract mutant
htt toxicity [13]. Consistent with this notion, gene expression
changes are not uniformly reversed in parallel with the modulation
of HD phenotype [14,15,16]. In the present study, we sought to
identify compensatory HD-related gene expression changes to
elucidate novel ways to promote neuronal viability.
Here we identify regulator of G-protein signaling 2 (RGS2) as a
novel modifier in primary striatal neuron models of HD. The RGS
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the presence of a conserved ,120 aa RGS domain necessary and
sufficient for binding Ga subunits of heterotrimeric G proteins.
RGS2 acts as an attenuator of signal transduction for GPCRs via
enhancement of the rate of hydrolysis of GTP to GDP by Gaq [17]
and Gai subunits [18,19]. RGS2 also interacts directly with
adenylyl cyclases 3 and 5 [20,21] to inhibit the synthesis of cAMP,
and modulates MAPK signaling [18,22].
In addition to identifying RGSs as a possible point of
intervention to combat striatal neurodegeneration in HD, the
present results suggest that the current view of HD-related effects
on neuronal gene expression needs to better account for pro-
survival autocompensatory responses.
Results
The aim of the present study was to identify HD-regulated
genes that might function as HD modifiers. We selected genes of
interest based on microarray gene expression data from HD brain
and HD model systems. A simple meta-analysis of data obtained
from human HD brain [10], mouse models of HD [9] and a
primary neuron model of HD (PGK-htt171-82Q; [23]) allowed us
to choose genes whose expression was decreased in all 3 systems
(Table 1). We further narrowed our selection of genes to those that
were known or suspected to participate in important striatal
neuron signaling processes. The following candidates were
subsequently chosen for functional testing.
a) Striatum-enriched phosphatase (STEP/Ptpn5): STEP is a
striatal neuron-enriched tyrosine phosphatase whose activity is
responsive to glutamatergic and dopaminergic afferents [24,25,26].
Reciprocally,STEPactivation hasbeenshown to negativelyregulate
NMDA receptor stimulation via dephosphorylating and promoting
the endocytosis of the NMDA receptor subunit NR2B [27].
b) Ras homolog enriched in striatum (Rhes/RASD2): RASD2 is
a member of the large ras superfamily of proteins [28,29].
Interestingly RASD2 knockout mice show a motor coordination
deficit [30] and therefore somewhat resemble HD model animals.
Moreover, RASD2 plays an important role in regulating
dopamine receptor signaling [31], a neurotransmitter system
known to be affected in HD [32,33].
c) RGS2 is known to be an important regulator of Gaq subunit
and Gai -containing heterotrimeric G-proteins, and adenylyl
cyclases [20,34]. G-protein-coupled receptor signaling and cAMP
signaling has been shown in previous studies to be significantly
abnormal in HD [7], providing a rationale for testing the ability of
RGS2 to compensate for such deficiencies.
d) Neuronatin (NNAT) is expressed during brain development
and is believed to regulate neuronal differentiation [35]. Previous
data in the neuron-like PC12 cell line suggests potential
neuroprotective effects of NNAT [36], leading us to hypothesize
that it might do the same in HD model systems.
We first used qPCR to assess differential expression of the above
genes in the TRE-htt171-82Q model of HD [37]. As expected
based on HD mouse studies, the qPCR results show progressive
decreases in STEP, RASD2, RGS2 and NNAT RNAs in TRE-
htt171-82Q compared to TRE-htt171-18Q cells (Fig. 1).
We next tested whether restoring the expression of these genes
modified the survival of htt171-82Q-exposed cells. For these
experiments, we implemented a primary striatal lentiviral model of
HD described previously [37]. As expected, lentivirus-mediated
expression of htt171-82Q resulted in a ,50% decrease in NeuN-
positive (neuronal) cells as compared to control cells expressing
htt171-18Q (Fig. 2). Co-expression of NNAT or STEP with
htt171-82Q did not influence htt toxicity, suggesting that these
genes do not have a major disease-modifying effect. In contrast,
the expression of RGS2 and RASD2 decreased the viability of
neurons expressing either htt171-18Q or htt171-82Q. In order to
rule out non-specific viral toxicity as an explanation for the
observed effects, we repeated the experiments with independent
batches of lentiviral vectors (not shown) and lower vector
concentrations (8 ng/ml or 2.5 ng/ml p24 antigen; Fig. 3). These
experiments showed that under conditions nontoxic to htt171-18Q
cells, both RGS2 and RASD2 still enhanced the toxicity of htt171-
82Q. These data indicate that RGS2 and RASD2 may exacerbate
HD-related neurotoxicity.
The above results suggested to us that decreasing levels of RGS2
and RASD2 might be beneficial to HD neurons. To investigate
this hypothesis, we used RNAi to further decrease the expression
of RGS2 and RASD2 in parallel with neuronal exposure to
htt171-82Q. Lentivirally-delivered shRNAs resulted in effective
silencing of both RGS2 and Rhes RNAs and proteins (Fig. 4A,B).
Moreover, as predicted, the silencing of both genes protected
against htt171-82Q toxicity (Fig. 4C).
Whereas a parallel study investigating the role of Rhes in
pathogenesis of HD had recently been described [38] (discussed
below), the mechanism of modulation of mutant htt toxicity by
RGS2 expression was unknown. Therefore, we conducted addi-
tional experiments to address this question. We first assessed
whether RGS2 expression had an effect on mutant htt levels or the
formation of htt inclusions (Fig. 5). Co-expression of RGS2 with
mutant htt again resulted in reduced neuronal survival compared to
co-expression of mutant htt with CFP as control. Although the total
number of mutant htt-positive nuclei was reduced when RGS2 was
expressed, this did not represent a change in nuclear accumulation
when corrected for neuronal number. Correspondingly, silencing of
RGS2 in cells expressing mutant htt increased the number of
Table 1. Expression of potential gene modifiers in different HD models and in human HD brain.
System
Gene Human HD R6/2 6 w R6/2 12 w CHL2 22 m
Primary striatal
neurons
Log2FC P value Log2FC P value Log2FC P value Log2FC P value Log2FC P value
RGS2 -0.54 6.81E-05 -0.37 7.50E-02 -1.16 9.11E-05 -0.73 1.88E-04 -1.19 7.53E-09
RASD2/Rhes -1.38 9.93E-12 -0.76 3.46E-05 -1.37 1.15E-05 -1.12 2.39E-07 -1.46 6.60E-09
Nnat -0.35 1.82E-06 -0.69 1.71E-03 -0.56 1.52E-03 -0.40 2.97E-02 -1.24 3.97E-05
Ptpn5/STEP -1.51 6.30E-10 -0.75 3.37E-05 -1.13 6.73E-06 -0.67 9.48E-06 -0.92 1.94E-07
RNA levels are presented as Log2 fold change (Log2FC) of the HD condition compared to control for each microarray experiment. Human caudate data are from [10],
R6/2 and CHL2 data are from [9], primary striatal neuron data are from [23].
doi:10.1371/journal.pone.0022231.t001
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htt, but not the ratio. These results led us to conclude that
modulation of htt toxicity by RGS2 expression levels is not due to a
major change in the aggregation or accumulation of mutant htt.
RGS2 acts as an attenuator of signal transduction for GPCRs via
enhancement of the rate of GTP hydrolysis by Gai [18,19] which
couples negatively to ACs. RGS2 has also been shown to interact
directly with AC3 and AC5 to inhibit the synthesis of cAMP
[20,21,39]. Importantly, cAMP signaling has been a proposed
deficit in HD brain [40,41], and AC5 is the prominent AC in
striatum, the most affected HD brain region. We therefore tested
the hypothesis that the reduced levels of RGS2 in HD might result
in a compensatory restoration in cAMP levels which could explain
the RGS2-mediated neuroprotective effect. We first assessed
whether modulation of RGS2 expression would influence cAMP
levels in striatal neurons in non-disease conditions (Fig. S1).
However, neither overexpression nor silencing of RGS2 changed
basal cAMP levels (as compared to CFP or shGFP controls,
respectively). Stimulation of cAMP biosynthesis with the D1
receptor agonist SKF-82958 resulted in an expected increase in
cAMP levels; however, this increase was not influenced significantly
by the corresponding expression levels of RGS2 (Fig. S1). We then
went on to test whether RGS2 silencing improves cAMP levels in
htt171-82Q-exposed neurons. These experiments demonstrated no
difference in cAMP level in neurons expressing htt171-82Q
compared to htt171-18Q (Fig. 6); moreover, decreasing RGS2
expression was without effect on cAMP levels in either basal or
stimulated conditions. We interpret these results to indicate that the
protective effect of RGS2 silencing observed in our model is not
explained by the modulation of cAMP biosynthesis.
We therefore considered other plausible mechanisms of RGS2-
mediated neuroprotection. Previous experiments in COS-7 cells
expressing M3 muscarinic receptors showed that RGS2 decreased
the phosphorylation and activation of ERK1/2 [18,22]. Since
ERK1/2 activation is a previously implicated mediator of
neuroprotection in HD models [42,43], we tested the hypothesis
that inhibiting RGS2 might also be effective by increasing ERK
activity. Interestingly, RGS2-silenced cells exposed to mutant
htt171-82Q demonstrated the hypothesized increase in ERK1/2
phosphorylation (Fig. 7); a non-statistically significant trend
towards increased ERK phosphorylation (after normalization for
ERK total protein levels) was also observed in Htt171-18Q cells
(Fig. S2). Conversely, Akt phosphorylation was unaffected by
RGS2 silencing (Fig. S3). Thus, we suggest that the enhancement
of ERK signalling may be the mechanism responsible for the
RGS2-silencing-induced neuroprotection.
Since ERK activation has been shown to be neuroprotective in
a number of contexts (for caveats, see Discussion), we also asked
whether RGS2 might be able to modulate neurotoxicity due to
mitochondrial stress. We therefore assessed its modulation of
neuronal viability following exposure of striatal neurons to the
mitochondrial toxin 3-nitropropionic acid (3NP). Whereas RGS2
overexpression decreased neuronal viability and enhanced 3NP
toxicity, silencing RGS2 protected primary striatal neurons from
these effects (Fig. 8). These results suggest that diminishing RGS2
activity may be neuroprotective against a number of toxic stimuli.
Figure 1. Timecourse of differential expression in the TRE-htt171-82Q primary striatal lentiviral model of HD. RGS2, RASD2, NNAT and
STEP RNA levels were measured by qPCR in primary striatal cells expressing mutant htt fragments under the control of a TRE promoter. Target RNA
levels (i.e those of RGS2, RASD2, NNAT, STEP) were normalized to the expression level of b-actin and expressed as % control relative to neurons
expressing htt171-18Q at the corresponding time point. (mean6SEM); n=4. * p,0.05; ** p,0.01; *** p,0.001.
doi:10.1371/journal.pone.0022231.g001
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gene expression in HD brain, these results indicate that the
downregulation of RGS2 and RASD2/Rhes expression comprise
autoprotective neuronal responses, rather than etiologic events, in
HD. Moreover, the data of the present study provide a novel
rationale for exploring RGS modulation of intracellular signalling as
a new possible avenue for the development of neuroprotective
therapies.
Discussion
In the present study, we investigated the functional consequenc-
es of disease-induced downregulation of the expression of several
important striatally expressed genes. The continued evaluation of
the downstream effects of HD-induced changes in gene regulation
is important to better understand mechanisms of disease
pathogenesis and also to identify novel therapeutic targets and
pathways that can modulate the course of the disease. The latter is
particularly important because no disease-modifying therapy for
HD exists to date.
We show in this report that individual gene expression changes
have different effects on HD progression, since restoring their
expression levels does not uniformly modify mutant htt’s effects.
Previous studies by our group and others have also suggested that
such heterogeneous effects might exist. For example, diminished
hippocalcin levels were also shown not to account for sensitization
to HD-related toxicities [37], similar to the results observed here
for NNAT and STEP.
Importantly, however, we also define another subset of gene
expression changes that appears to represent an autocompensatory
neuronal response to mutant htt accumulation. One such HD-
modifying compensatory response is the downregulation of
RASD2/Rhes. An important parallel study implicating Rhes in
the pathogenesis of HD was also published recently [38]. Our
demonstration that reduction of RASD2/Rhes expression protects
striatal neurons from mutant htt is thus concordant with these
independently obtained results (in non-neuronal cells). Subrama-
niam et al. have further provided evidence that Rhes-enhanced
sumoylation of mutant htt increases its cytotoxicity. An earlier
study suggested that the expression of another striatally enriched
gene, CalDAG-GEF1, might account for the brain regional
selectivity of mutant htt toxicity [13], by demonstrating that the
CalDAG-GEF1 is downregulated in HD human caudate and in
R6/2 mice striatum and that silencing of this gene protects
neurons from toxicity induced by mutant htt in an organotypic
cortico-striatal slice model of HD. Although it is not possible to
state for certain that the HD-affected neuron senses and actively
compensates for mutant htt’s effects, the end results are clearly
beneficial rather than etiologic.
In the present study we identified RGS2 as a novel modifier of
HD neurotoxicity. The decreased RGS2 expression observed in
HD also seems to be compensatory, since restoration of RGS2
Figure 2. Effects of restoring downregulated RNAs in the TRE-htt171-82Q primary striatal model of HD. Primary striatal neurons were
infected on DIV1 with lentiviral vectors encoding WT (18Q) or mutant (82Q) htt171 fragments under the control of a TRE promoter and co-infected on
DIV4 with vectors encoding RGS2, RASD2, NNAT, STEP or CFP (control) at a concentration of 25 ng p24 antigen/ml. Neuronal viability was assessed
after 3 weeks in culture by quantification of NeuN-positive cells. * indicates significance of mutant htt effects; + indicates significance of effects of
the candidate modifier expression. Data are presented as mean6SEM, n=15, expressed as % control (relative to WT htt171-18Q+CFP). * p,0.05;
** p,0.01; *** p,0.001.
doi:10.1371/journal.pone.0022231.g002
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expression conversely results in neuroprotection. The best-known
function of RGS2 is its RGS-domain-mediated attenuation of
GPCR-mediated signalling. Our interest in the RGS family of
genes was peaked by previous findings that heterotrimeric GPCR
signaling is significantly altered in HD [7,10,23]. We were
somewhat surprised to observe that the modulation of cAMP
levels was not a significant contributor to htt toxicity in our model
system. However, the HD-induced changes in cAMP levels have
been debated, and are likely to comprise a set of potentially
complex and dynamic effects [44,45,46,47]. Moreover, some
effects attributed to deficient cAMP-related gene regulation invoke
downstream steps of transcriptional activation [40,41] rather than
proximal signal transduction events.
We have not ruled out the possible role of RGS2 in regulating
other GPCRs important for striatal function. We have determined,
however, that negative regulation of RGS2 expression results in an
increase in ERK2 phosphorylation that likely explains, at least in
part, its neuroprotective effect. Although ERK’s effects on
neurodegeneration in other conditions has been debated [48,49],
previous studies have been concordant in showing that ERK
activation achieves neuroprotection against HD when ERK is
regulated endogenously, regulated by small molecules, or activated
via BDNF signaling [42,43,50,51]
Our studies suggest that RGS2 antagonists might be an
interesting area for development of anti-neurodegenerative disease
therapeutics. This idea is further supported by the fact that RGS2
knock-out mice show increased survival of retinal ganglion cells
[52]. However, other studies of RGS2 null-mutant animals suggest
proceeding with caution. For example, hypertension and deficien-
cies in T-cell activation have been reported [53].
Intriguingly, the expression levels of other members of the RGS
gene family are also changed in HD models and human HD brain
[7,10,23]. Since these factors are also potentially important
regulators of GPCR signaling, which is impaired in HD, other
RGS family members function may also be an interesting subject of
further investigation. This is particularly true since this family of
proteins is generally considered amenable to small-molecule
therapeutics.
Materials and Methods
Ethics Statement
All experiments were approved by the local veterinary office
and the Commission for Animal Experimentation of the Canton
of Vaud Switzerland, authorization number 1667.2 issued
by the Service de la consommation et des affaires ve ´te ´rinaires
(SCAV)
Figure 3. Effects of candidate modifiers at lower expression levels in the TRE-htt171-82Q primary striatal neuron model of HD.
Primary striatal neurons were infected on DIV1 with lentiviral constructs encoding WT (18Q) or mutant (82Q) htt171 fragments under the control of a
TRE promoter and co-infected on DIV4 with constructs encoding RGS2, RASD2, or CFP (control) at the concentration of 8 or 2.5 ng p24 antigen/ml.
Neuronal viability was assessed after 3w in culture by quantification of NeuN-positive cells. * indicates significance of mutant htt effects; + indicates
significance of effects of candidate modifier expression. Values are presented as mean6SEM, n=15, expressed as % control (WT htt171-18Q+CFP).
*p ,0.05; ** p,0.01; *** p,0.001.
doi:10.1371/journal.pone.0022231.g003
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Rat cDNAs encoding RGS2 (NM_053453.2), RASD2
(NM_133568.1), PTPN5 (NM_019253.3) and NNAT transcript
variant 2 (NM_181687.1) were amplified from total rat brain cDNA
using the polymerase chain reaction (PCR) and cloned into the
shuttle plasmid pENTR/D-TOPO (Invitrogen, Carlsbad, CA,
USA) using the pENTR Directional TOPO Cloning Kit (Invitro-
gen). The cDNAs were then transferred from the shuttle vector into
a self-inactivating lentiviral plasmid vector with a woodchuck
hepatitis virus posttranscriptional regulatory element (SIN-W) under
the control of the mouse phosphoglycerate kinase 1 (PGK) promoter
using Invitrogen’s GatewayTM recombination technology. The
Figure 4. Silencing of RGS2 or RASD2 is protective in the TRE-htt171-82Q primary striatal neuron model of HD. A RGS2-targeting
shRNA delivered via a lentiviral vector resulted in a 46.167.2% reduction of RGS2 mRNA (in neurons) and 4065.4% reduction of RGS2 protein
expression (in HEK 293T cells), respectively (Panel A). A RASD2-targeting shRNA resulted in a 76.860.3% reduction of RASD2 mRNA expression (in
neurons) and 79.163.6% reduction of RASD2 protein expression (in HEK 293T cells), respectively (Panel B). Immunoblots were performed on HEK 293
cells expressing HA-tagged RGS2 and RGS2 silencing constructs. Lentiviral delivery of an shRNA targeting GFP (shGFP) was used as a control. Values
are presented as mean6SEM, n=3. * p,0.05; ** p,0.01; *** p,0.001. (Panel C). Primary striatal neurons were infected on DIV1 with lentiviral vectors
encoding WT (18Q) or mutant (82Q) htt171 fragments under the control of a TRE promoter and co-infected on DIV4 with shRNA vectors targeting
RGS2, RASD2, or GFP (control) at a concentration of of 1 ng p 24 antigen/ml. Neuronal viability was assessed by NeuN counting as described in Fig. 2.
doi:10.1371/journal.pone.0022231.g004
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construct targeting the rat RASD2 sequence AGAAGAACAC-
GAACGUAAA (with UUCAAGAGA used as the loop sequence).
An shRNA-generating construct for rat RGS2 was obtained from
Sigma in a pLKO.1-puro vector (targeting sequence GAT-
GAACTGCTGGCCAGTAAA (TRCN0000054762)).
Lentiviral vectors were produced in human embryonic kidney
293T (HEK293T) cells with a four-plasmid system as described
previously [37]. The viruses were resuspended in PBS with 1% of
BSA and the particle content was assessed by p24 antigen ELISA
(RETROtek; Gentaur).
In vitro lentiviral model of Huntington’s disease
Primary cultures of striatal neurons were prepared and infected
at DIV1 with lentiviral vectors as described in [37]. Htt-expressing
lentiviruses encoding the first 171 amino acids of wild-type or
mutant human htt, (SIN-W-TRE-htt171-18/82Q, respectively)
were applied at a particle concentration of 25 ng p24 antigen/ml
culture medium together with a vector encoding the tetracycline-
controlled transactivator tTA1 under the control of PGK
promoter (at a concentration of 40 ng p24/ml). At DIV4 neurons
were infected with lentiviral expression constructs for RGS2,
RASD2, NNAT or PTPN5 (at a p24 concentration of 25 ng/ml
or 8.3 ng/ml) or with lentiviral silencing constructs for RGS2 and
RASD2 (at a p24 concentration of 1 ng/ml). Vectors expressing
CFP or an shRNA targeting green fluorescent protein were used as
controls for expression and silencing studies, respectively. Three
weeks after the infection of htt constructs, cells were fixed and their
survival assessed by NeuN counting [37].
3-Nitropropionic acid toxicity studies
Primary cultures of striatal neurons were prepared as in [37]
and infected at DIV4 with lentiviral constructs for expression or
Figure 5. Modulation of RGS2 expression does not influence nuclear accumulation of mutant htt. Primary striatal neurons were infected
on DIV1 with lentiviral constructs encoding WT (18Q) or mutant (82Q) htt171 fragments under the control of a TRE promoter and co-infected on DIV4
with an RGS2 expression vector as described in Fig. 2B (A) or RGS2 silencing construct as in Fig. 4B (B). NeuN-positive and 2B4-positive nuclei were
quantified as described in the Methods section. (C) Top: representative images of NeuN and 2B4 staining; scale bar 100 mm. Bottom: Representative
higher magnification images showing the continued presence of 2B4-positive nuclei after RGS2 silencing; scale bar =10 mm.
doi:10.1371/journal.pone.0022231.g005
Figure 6. RGS2 silencing does not influence cAMP levels in
htt171-82Q-expressing primary striatal neurons. Primary striatal
neurons were exposed to htt171-18Q- or htt171-82Q-encoding vectors
and RGS2 shRNA (or control GFP shRNA) as described in Fig. 4B. After
2.5 weeks in culture, levels of cAMP were measured in basal conditions
and after stimulation with 10 mM SKF-82958 for 15 min. Data are
presented as mean6SEM, n=6.
doi:10.1371/journal.pone.0022231.g006
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100 or 300 uM 3-nitropropionic acid (3-NP). Forty-eight hours
later cells were fixed and their survival assessed by NeuN-positive
cell counting.
Immunocytochemistry. Cells were fixed in 4% parafor-
maldehyde for 20 min at RT, washed with PBS and blocked by
incubation in PBS containing 10% normal goat serum (NGS,
Gibco, Invitrogen, Basel, Switzerland) and 0.1% Triton X-100
(TX, Fluka, Sigma, Buchs, Switzerland). Cells were incubated
with primary antibodies for 1h at RT (anti-Neuronal Nuclei
(NeuN) (Chemicon MAB377 clone A60; 1:500) or anti-huntingtin
(Chemicon MAB5492 clone 2B4; 1:500)), washed in PBS and
incubated for 1 h at RT with fluorescent secondary antibody
(Alexa-Fluor 488, A21121, Invitrogen; 1:1000). Where indicated,
nuclei were stained with Hoechst 33342 dye (Invitrogen, Basel,
Switzerland). Images of NeuN-labeled cultures (n=15 per
condition) and of 2B4-labeled cultures (n=6 per condition) were
acquired using fully automated BD Pathway 855 (BD Biosciences,
San Diego, USA) microscope under non-saturating exposure
conditions, using the same acquisition settings for all samples in a
given experiment. Counting of nuclei was performed with ImageJ
software (NIH, Bethesda, MD, USA) applying intensity and size
thresholds. Neurons with accumulation of htt in the nucleus as
determined by 2B4 staining were counted as htt-accumulation
positive.
qPCR
Total RNA was extracted using the RNeasy kit (Qiagen) and
500 ng of total RNA were used for cDNA synthesis employing
High Capacity cDNA RT kit (Applied Biosystems). Quantitative
real-time PCR was performed on a 7900HT Real-Time PCR
System with SDS 2.3 software (Applied Biosystems) using TaqMan
Universal PCR Mastermix (Applied Biosystems). Relative expres-
sion (V) was calculated by normalization of gene expression to b-
actin expression as described in [54]. All qPCR reactions were
performed in triplicate. The following TaqMan assays obtained
from Applied Biosystems were used: b-actin Rn00667869_m1;
RGS2 Rn00584932; RASD2 Rn00592054; NNAT Rn00822063;
PTPN5 Rn00570437_m1.
Statistical analyses
Numerical data represent the mean values 6 SEM. The one-
way ANOVA was used to compare multiple conditions and the
two-tailed Student’s t-test was used for two-group comparisons.
p , 0.05 was set as the threshold for statistical significance.
cAMP assay
cAMP measurements were performed using the Direct cAMP
ELISA kit (CA-200, Sigma-Aldrich), according to the protocol
supplied by the manufacturer. Primary striatal cultures at 2.5
weeks in culture were stimulated with 10 mM Forskolin or 10 mM
Figure 7. RGS2 silencing increases ERK2 phosphorylation in
neurons expressing mutant htt. Primary striatal neurons were
infected with htt171-82Q expression and RGS2 silencing vectors as
described in Fig. 4B. After 2.5 weeks in culture, levels of ERK1/2
phosphorylation were measured by immunoblot. Data are presented as
mean6SEM, n=6, normalized to htt171-82Q+shGFP control. * p,0.05.
doi:10.1371/journal.pone.0022231.g007
Figure 8. RGS2 levels modulate 3NP toxicity. Primary striatal
neurons were infected on DIV 4 with an RGS2 lentiviral expression
vector at a concentration of 8 ng/ml p24 (A) or a lentiviral silencing
construct targeting RGS2 at concentration of 1 ng/ml p24 (B). Vectors
encoding CFP or shGFP were used as controls (in A and B, respectively).
After 2 weeks in culture, neurons were treated with 100 or 300 uM 3NP.
Neuronal viability was assessed after 48 h by NeuN counting.
doi:10.1371/journal.pone.0022231.g008
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HCl. The supernatant was recovered by centrifugation after which
a small aliquot of lysate (10 ml) was used to determine protein
concentration using the BCA protein assay (Pierce). The
acetylation procedure was employed to increase assay sensitivity.
cAMP measurements were normalized to total protein. A
minimum of 4 samples per condition were assayed.
Immunoblot experiments
For analysis of phosphoproteins, primary striatal neurons were
harvested in RIPA buffer (Sigma), containing protease inhibitor
cocktail (Sigma), phosphatase inhibitor cocktails 1 and 2 (Sigma)
and PMSF 1 mM. Proteins were separated on 12% SDS-
polyacrylamide gels and transferred to nitrocellulose membrane.
Membranes were blocked for one hour in 30% OdysseyH Blocking
Buffer in PBS (LI-COR Biosciences) followed by incubation with
primary antibodies diluted in Blocking Buffer with 0.1% Tween-
20 overnight at 4uC. Membranes were rinsed with 0.1% Tween-
20/PBS followed by incubation with secondary antibody diluted in
Blocking Solution for one hour at RT. After final rinses, blots were
scanned with an OdysseyH Infrared Imager and densitometric
measurements were obtained using Odyssey software (LI-COR
Biosciences). For the detection of pERK1/2 images were acquired
using ImageQuant LAS 4000 (GE Healthcare). Primary and
secondary antibodies comprised: mouse anti-phospho-Erk1/2
(Millipore 05-481, 1:1000), rabbit anti total ERK1/2 rabbit
(Millipore 06-182, 1:1000), rabbit anti-HA tag (Covance MMS-
101R, 1:2000), rabbit anti-a-tubulin (Abcam ab4074, 1:2000),
donkey anti-mouse IRDye 800CW (LI-COR Biosciences,
1:15000), donkey anti-rabbit IRDye 680 (LI-COR Biosciences,
1:15000), anti-mouse-HRP (Jackson ImmunoResearch, 1:10000).
Human embryonic kidney 293T cell culture and
transfection
Human embryonic kidney (HEK) 293T cells (ATCC CRL-
11268) were cultured in the DMEM (Invitrogen) with 10% fetal
bovine serum and Pen-Strep at 37uC in 5% CO2/air atmosphere.
A CaPO4-based procedure was used to transfect the cells for RNAi
experiments. 0.5 mg of cDNA vectors and 0.02 mg of silencing
vectorswere used for2610
5 cells.Theculture mediumwaschanged
6 hours post-transfection and protein was harvested 48 h later.
Supporting Information
Figure S1 cAMP levels are not changed by modulation
of RGS2 expression in primary striatal neurons. Primary
striatal neurons were infected with an RGS2-encoding construct as
in Fig. 3 (A) or an RGS2 silencing construct as in Fig. 4A (B). After
2 weeks in culture, levels of cAMP were measured in basal
conditions and after stimulation with 10 mM SKF-82958 for 15
min. Values are presented as mean6SEM, n=3. NS – non
significant.
(TIF)
Figure S2 RGS2 silencing effect on ERK2 phosphoryla-
tion in neurons expressing wild type htt. Primary striatal
neurons were infected with htt171-18Q expression and RGS2
silencing vectors as described in Fig. 4B. After 2.5 weeks in culture,
levels of ERK2 phosphorylation were measured by immunoblot.
Data are presented as mean6SEM, n=5, normalized to htt171-
82Q+shGFP control. ** p,0.01.
(TIF)
Figure S3 RGS2 silencing effect on Akt phosphorylation
in neurons expressing mutant htt. Primary striatal neurons
were infected with htt171-82Q expression and RGS2 silencing
vectors as described in Fig. 4B. After 2.5 weeks in culture, levels
of Akt phosphorylation were measured by immunoblot. Data
are presented as mean6SEM, n=6, normalized to htt171-82Q
+shGFP control.
(TIF)
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